Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: An open pilot study

Annals of the Rheumatic Diseases

Volumn 59, Issue 6, 2000, Pages 428-433

  Van Den Bosch, Filip ^a   Kruithof, Elli ^a   Baeten, Dominique ^a   De Keyser, Filip ^a   Mielants, Herman ^a   Veys, Eric M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOSE RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REMISSION; SPONDYLOARTHROPATHY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DRUG THERAPY, COMBINATION; EVALUATION STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PILOT PROJECTS; PREDNISOLONE; PSORIASIS; SPONDYLITIS; SPONDYLITIS, ANKYLOSING; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034130272     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.6.428     Document Type: Article

References (28)

1. 1 Wright V. Seronegative polyarthritis - a unified concept. Arthritis Rheum 1978;21:618-33.
2. 2 Mielants H, Veys EM, Cuvelier C, De Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol 1988;27(suppl 2):95-105.
3. 3 Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, et al. The evolution of the spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995;22:2266-72.
4. 4 De Vos M, Mielants H, Cuvelier C, Elewaut D, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110:1696-703.
5. 5 Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995;22:2273-8.
6. 6 Dick AP, Grayson MJ, Carpenter RC, Petrie A. Controlled trial of sulfasalazine in the treatment of ulcerative colitis. Gut 1964;5:437-42.
7. 7 Van Hees PA, Van Lier HJ, Van Elteren PH, Driessen M, Van Hogezand RA, Ten Velde GP, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981;22:404-9.
8. 8 Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
9. 9 Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
10. 10 Van Dullemen HM, Van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
11. 11 Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
12. 12 Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-405.
13. 13 Antoni C, Dechant C, Lorenz H, Olgivie A, Kalden-Nemeth D, Kalden J, et al. Successful treatment of severe psoriatic arthritis with infliximab [abstract]. Arthritis Rheum 1999;42(suppl):A1801.
14. 14 Mease P, Goffe B, Metz J, Vanderstoep A. Enbrel® (etanercept) in patients with psoriatic arthritis and psoriasis [abstract]. Arthritis Rheum 1999;42 (suppl):A1835.
15. 15 Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
16. 16 Kavanaugh AF. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:593-614.
17. 17 Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41: 1552-63.
18. 18 Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
19. 19 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
20. 20 Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21: 2286-91.
21. 21 Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
22. 22 Dougados M, Gueguen A, Nakache JP, Nguyen M, Mery C, Amor B. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988;15: 302-7.
23. 23 Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
24. 24 Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
25. 25 Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9.
26. 26 De Keyser F, Van Damme N, De Vos M, Mielants H, Veys EM. Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm Res 2000;49:47-54.
27. 27 Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994;91:8562-6.
28. 28 Yin Z, Braun J, Neure L, Wu P, Liu L, Eggens U, et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum 1997;40:1788-99.